Results 101 to 110 of about 89,305 (304)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Lung Cancer: Targets and Therapy, 2011
Masayuki Takeda1, Isamu Okamoto1, Yasumasa Nishimura2, Kazuhiko Nakagawa11Department of Medical Oncology, 2Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka, JapanAbstract: The epidermal growth factor receptor (EGFR) is a ...
Takeda M, Okamoto I, Nishimura Y, Nakagawa K   +3 more
doaj  

Application of Genetically-Engineered Anti-CEA Antibodies for Potential Immunotherapy of Colorectal Cancer

The International Journal of Biological Markers, 1992
Hitherto anti-CEA monoclonal antibodies (MAbs), normally of mouse origin, have been used primarily for clinical diagnosis of colorectal cancer, either as a tumor marker in serum to monitor tumor recurrence, or latterly as a means to localize in vivo CEA ...
N. Hardman, B. Murray, M. Zwickl, F. Kolbinger, G. Pluschke   +4 more
doaj   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Humanized Antibodies. Modern Developments and Prospects for the Creation of Medical Protectors Against Biological Threads and Hazards

Вестник войск РХБ защиты
Passive immunization is the variant of the immunization, in which antibodies are introduced into the body in quantities, sufficient to provide a therapeutic effect.
A. S. Gorshkov, D. V. Pechenkin, A. V. Kuznetsovskiy, D. V. Borovskoy   +3 more
doaj   +1 more source

Anticuerpos monoclonales. Aspectos básicos

Neurología, 2011
Resumen: Introducción: Los anticuerpos monoclonales son una poderosa herramienta para el diagnóstico de laboratorio y un instrumento cada vez más utilizado en el tratamiento de diversas enfermedades.
A. García Merino
doaj   +1 more source

Biotech drugs : biological therapeutic agents [PDF]

, 2009
The recent years has seen significant growth in a new therapeutic approach to the management of disease. Biological therapeutic agents, constitute a broad category of drugs, usually generated by recombinant techniques from living organisms.
Fenech, Anthony G., Grech, Godfrey
core   +1 more source

Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet, Anna Largajolli, Petra M. Jauslin, Emilie Schindler, Mourad Hamimed, Wannee Kantasiripitak, Antonio Gonçalves, Eline Van Maanen, Khaled Benkali, Tomohisa Saito, Jonathan I. Silverberg, Andreas Wollenberg, Michael Graeber, Liliana Ulianov, Christophe Piketty, Luca Loprete, Vincent Duval, Nathalie Wagner   +17 more
wiley   +1 more source

Radiopharmaceuticals in immunoscintigraphy and radioimmunotherapy

Nucleus, 2012
The high morbidity-mortality of cancer makes this condition in Cuba, and at international level, a serious health problem. Radioimmunodiagnosis and radioimmunotherapy based in the growing biotechnological advances, and the actual knowledge of molecular
René Leyva Montaña
doaj  

Monoclonal antibodies. Basic features

Neurología (English Edition), 2011
Introduction: Monoclonal antibodies are a powerful tool in laboratory diagnosis and are increasingly used in the treatment of several diseases. Development: Antibody development and characterization has a long history and goes back to immunology itself ...
A. García Merino
doaj   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source